Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-FIRST AML1718: venetoclax added to FLAI induction for newly diagnosed non-M3 acute myeloid leukemia
2023-510517-26-00Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Composite complete remission rate. Started Oct 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510517-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510517-26-00.